Gynecologic Oncology
RSSArticles
-
How you can remove HPV vaccination barriers
-
Use key instructions for correct condom use
-
Condom technology is now focus of research
The Bill & Melinda Gates Foundation has just released funding to support 11 projects that aim to improve uptake and regular use of male and female condoms by developing new designs that significantly preserve or enhance pleasure and simplify use. -
FDA eyes LNG ECP label change in light of research on weight impact
Labeling for the European levonorgestrel (LNG) emergency contraceptive pill NorLevo has been revised due to data indicating lower drug efficacy in women weighing 165 pounds and above. This move has led U.S. regulators to assess data on similar products. -
Multipurpose methods show research advances
Strides are being made in development of multipurpose prevention technologies, defined as a single product or strategy configured for at least two sexual and reproductive health prevention indications: unintended pregnancy, HIV, and other sexually transmitted infections. -
How to address deaths from ovarian cancer
A woman in her late 40s dies less than a year after ovarian cancer is diagnosed. She has three daughters ranging from 15 to 25 years of age. How can ovarian cancer be prevented in these three young women? How can ovarian cancer be prevented during the lifetime of ANY woman, whether or not she has a family history of ovarian cancer?
-
Strategy to Overcome Rituximab Resistance in Patients with Indolent Lymphoma
In a Phase 2 study, Ahmadi and colleagues demonstrate reasonably high response rates in rituximab-resistant indolent lymphoma patients sequentially treated with lenalidomide/dexamethasone (Part 1; 2 monthly cycles) followed by lenalidomide/dexamethasone + weekly rituximab (Part 2; 3 monthly cycles). -
Second-line Docetaxel Improves Survival and Symptom Control in Advanced Esophagogastric Cancer
Patients with progressive advanced esophagogastric adenocarcinoma treated with docetaxel in addition to active symptom control (ASC) survived 44% longer than those who received ASC alone. -
Bendamustine-Bortezomib-Dexamethasone for Relapsed Myeloma
In a Phase 2 trial, Ludwig and colleagues present data on 79 patients with relapsed or refractory myeloma who were treated with bendamustine in combination with bortezomib and dexamethasone. -
Toward More Effective Neoadjuvant Breast Cancer Therapy
In a Phase 3, randomized clinical trial of primary systemic therapy for patients with early, locally advanced breast cancer, the addition of capecitabine to each of six 3-weekly cycles of epirubicin-docetaxel resulted in a 1.64 fold increase in the possibility of primary tumor pathologic complete response.